{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T10:11:21Z","timestamp":1778667081935,"version":"3.51.4"},"reference-count":69,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["53599199"],"award-info":[{"award-number":["53599199"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001407","name":"Department of Biotechnology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004541","name":"Ministry of Education, India","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004541","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001403","name":"Indian Institute of Technology Kanpur","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001403","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thrombosisresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.thromres.2026.109655","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:20:15Z","timestamp":1773361215000},"page":"109655","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Optimized AAVrh10 and Factor 9 vectors demonstrate improved phenotypic rescue in hemophilia B mice"],"prefix":"10.1016","volume":"260","author":[{"given":"Shamshul","family":"Huda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohankumar B.","family":"Senthilkumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dikshika","family":"Bihani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pratiksha","family":"Sarangi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Narendra Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dinesh","family":"Chandra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giridhara R.","family":"Jayandharan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2026.109655_bb0005","series-title":"Report on the annual global survey","author":"World Federation of Hemophilia","year":"2023"},{"issue":"8","key":"10.1016\/j.thromres.2026.109655_bb0010","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1080\/17474086.2018.1489719","article-title":"The benefits of prophylaxis in patients with hemophilia B","volume":"11","author":"Castaman","year":"2018","journal-title":"Expert Rev. Hematol."},{"issue":"12","key":"10.1016\/j.thromres.2026.109655_bb0015","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1111\/jth.15506","article-title":"Detailed analysis of anti-emicizumab antibody decreasing drug efficacy, using plasma samples from a patient with hemophilia a","volume":"19","author":"Kaneda","year":"2021","journal-title":"J. Thromb. Haemost."},{"issue":"6","key":"10.1016\/j.thromres.2026.109655_bb0020","first-page":"344","article-title":"Diagnosis and treatment of hemophilia","volume":"17","author":"Kizilocak","year":"2019","journal-title":"Clin. Adv. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.thromres.2026.109655_bb0025","doi-asserted-by":"crossref","DOI":"10.1186\/1750-1172-7-24","article-title":"Past, present and future of hemophilia: a narrative review","volume":"7","author":"Franchini","year":"2012","journal-title":"Orphanet J. Rare Dis."},{"issue":"2","key":"10.1016\/j.thromres.2026.109655_bb0030","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.tibtech.2017.11.006","article-title":"Engineering the delivery system for CRISPR-based genome editing","volume":"36","author":"Glass","year":"2018","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.thromres.2026.109655_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2019.107453","article-title":"Adeno-associated viral vector-mediated immune responses: understanding barriers to gene delivery","volume":"207","author":"Nidetz","year":"2020","journal-title":"Pharmacol. Ther."},{"issue":"4","key":"10.1016\/j.thromres.2026.109655_bb0040","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41576-019-0205-4","article-title":"Engineering adeno-associated virus vectors for gene therapy","volume":"21","author":"Li","year":"2020","journal-title":"Nat. Rev. Genet."},{"issue":"12","key":"10.1016\/j.thromres.2026.109655_bb0045","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0188830","article-title":"Cellular selectivity of AAV serotypes for gene delivery in neurons and astrocytes by neonatal intracerebroventricular injection","volume":"12","author":"Hammond","year":"2017","journal-title":"PLoS One"},{"issue":"25","key":"10.1016\/j.thromres.2026.109655_bb0050","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1056\/NEJMoa1108046","article-title":"Adenovirus-associated virus vector\u2013mediated gene transfer in hemophilia B","volume":"365","author":"Nathwani","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"10.1016\/j.thromres.2026.109655_bb0055","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa1407309","article-title":"Long-term safety and efficacy of factor IX gene therapy in hemophilia B","volume":"371","author":"Nathwani","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2026.109655_bb0060","doi-asserted-by":"crossref","DOI":"10.1177\/10760296251378455","article-title":"Recent advances in gene therapy for hemophilia","volume":"31","author":"Pang","year":"2025","journal-title":"Clin. Appl. Thromb. Hemost."},{"issue":"12","key":"10.1016\/j.thromres.2026.109655_bb0065","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1056\/NEJMoa2302982","article-title":"Gene therapy with fidanacogene elaparvovec in adults with hemophilia B","volume":"391","author":"Cuker","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.thromres.2026.109655_bb0070","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1056\/NEJMoa2211644","article-title":"Gene therapy with etranacogene dezaparvovec for hemophilia B","volume":"388","author":"Pipe","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.thromres.2026.109655_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2024.101273","article-title":"Global Seroprevalence of Neutralizing Antibodies against Adeno-Associated Virus (AAV) Serotypes of Relevance to Gene Therapy","volume":"32","author":"Chhabra","year":"2024","journal-title":"Mol. Ther. Methods Clin. Dev."},{"issue":"5","key":"10.1016\/j.thromres.2026.109655_bb0080","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/s41434-024-00441-5","article-title":"Multicenter assessment and longitudinal study of the prevalence of antibodies and related adaptive immune responses to AAV in adult males with hemophilia","volume":"31","author":"Pabinger","year":"2024","journal-title":"Gene Ther."},{"issue":"2","key":"10.1016\/j.thromres.2026.109655_bb0085","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/gt.2014.103","article-title":"10 Immunogenicity in mice and humans. Relevance of antibody cross-reactivity in human gene therapy","volume":"22","author":"Thwaite","year":"2015","journal-title":"Gene Ther."},{"issue":"6","key":"10.1016\/j.thromres.2026.109655_bb0090","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1089\/hum.2009.182","article-title":"Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors","volume":"21","author":"Boutin","year":"2010","journal-title":"Hum. Gene Ther."},{"issue":"1","key":"10.1016\/j.thromres.2026.109655_bb0095","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1182\/blood-2005-12-5115","article-title":"Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia a mice and dogs","volume":"108","author":"Jiang","year":"2006","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.thromres.2026.109655_bb0100","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1038\/mt.2015.179","article-title":"Comparative study of liver gene transfer with AAV vectors based on natural and engineered AAV capsids","volume":"23","author":"Wang","year":"2015","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.thromres.2026.109655_bb0105","doi-asserted-by":"crossref","first-page":"15941","DOI":"10.1038\/s41598-024-66546-4","article-title":"Seroprevalence of adeno-associated virus types 1, 2, 3, 4, 5, 6, 8, and 9 in a Basque cohort of healthy donors","volume":"14","author":"Navarro-Oliveros","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.thromres.2026.109655_bb0110","doi-asserted-by":"crossref","DOI":"10.1177\/10430342251366208","article-title":"Total and neutralizing antibody seroprevalence of hepatotropic adeno-associated virus among healthy and hemophilia A or B population from India","author":"Daniel","year":"2025","journal-title":"Hum. Gene Ther."},{"issue":"7\u20138","key":"10.1016\/j.thromres.2026.109655_bb0115","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1089\/hum.2021.287","article-title":"Global seroprevalence of pre-existing immunity against AAV5 and other AAV serotypes in people with hemophilia a","volume":"33","author":"Klamroth","year":"2022","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.thromres.2026.109655_bb0120","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2017.00441","article-title":"Optimized AAV rh. 10 vectors that partially evade neutralizing antibodies during hepatic gene transfer","volume":"8","author":"Selot","year":"2017","journal-title":"Front. Pharmacol."},{"issue":"9","key":"10.1016\/j.thromres.2026.109655_bb0125","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1002\/jgm.1496","article-title":"RH10 provides superior transgene expression in mice when compared with natural AAV serotypes for neonatal gene therapy","volume":"12","author":"Hu","year":"2010","journal-title":"J. Gene Med."},{"key":"10.1016\/j.thromres.2026.109655_bb0130","article-title":"101HEMB01 is a phase 1\/2 open-label, single ascending dose-finding trial of DTX101 (AAVrh10FIX) in patients with moderate\/severe hemophilia B that demonstrated meaningful but transient expression of human factor IX (hFIX)","volume":"130","author":"Pipe","year":"2017","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.thromres.2026.109655_bb0135","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1093\/nar\/12.2.857","article-title":"Compilation and analysis of sequences upstream from the translational start site in eukaryotic mRNAs","volume":"12","author":"Kozak","year":"1984","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"10.1016\/j.thromres.2026.109655_bb0140","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ymthe.2017.12.007","article-title":"Hyperactive factor IX Padua: a game-changer for hemophilia gene therapy","volume":"26","author":"VandenDriessche","year":"2018","journal-title":"Mol. Ther."},{"issue":"17","key":"10.1016\/j.thromres.2026.109655_bb0145","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1056\/NEJMoa0904377","article-title":"X-linked thrombophilia with a mutant factor IX (factor IX Padua)","volume":"361","author":"Simioni","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"24","key":"10.1016\/j.thromres.2026.109655_bb0150","doi-asserted-by":"crossref","first-page":"4964","DOI":"10.1111\/febs.15013","article-title":"Post-translational modifications in capsid proteins of recombinant adeno-associated virus (AAV) 1-rh10 serotypes","volume":"286","author":"Mary","year":"2019","journal-title":"FEBS J."},{"issue":"Suppl. 18","key":"10.1016\/j.thromres.2026.109655_bb0155","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1186\/1471-2105-16-S18-S9","article-title":"Prediction of neddylation sites from protein sequences and sequence-derived properties","volume":"16","author":"Yavuz","year":"2015","journal-title":"BMC bioinformatics"},{"issue":"1","key":"10.1016\/j.thromres.2026.109655_bb0160","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1089\/104303401450988","article-title":"Isolation of highly infectious and pure adeno-associated virus type 2 vectors with a single-step gravity-flow column","volume":"12","author":"Auricchio","year":"2001","journal-title":"Hum. Gene Ther."},{"issue":"1","key":"10.1016\/j.thromres.2026.109655_bb0165","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1089\/hgtb.2011.034","article-title":"Universal real-time PCR for the detection and quantification of adeno-associated virus serotype 2-derived inverted terminal repeat sequences","volume":"23","author":"Aurnhammer","year":"2012","journal-title":"Human Gene Therapy, Part B: Methods"},{"issue":"1","key":"10.1016\/j.thromres.2026.109655_bb0170","doi-asserted-by":"crossref","first-page":"21532","DOI":"10.1038\/s41598-020-78521-w","article-title":"A comparison of AAV-vector production methods for gene therapy and preclinical assessment","volume":"10","author":"Davidsson","year":"2020","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.thromres.2026.109655_bb0175","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1007\/s00277-018-3264-2","article-title":"Variants in FIX propeptide associated with vitamin K antagonist hypersensitivity: functional analysis and additional data confirming the common founder mutations","volume":"97","author":"Pezeshkpoor","year":"2018","journal-title":"Ann. Hematol."},{"issue":"6","key":"10.1016\/j.thromres.2026.109655_bb0180","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1182\/blood-2004-01-0138","article-title":"Creation of a mouse expressing defective human factor IX","volume":"104","author":"Jin","year":"2004","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.thromres.2026.109655_bb0185","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/ijlh.14171","article-title":"High variability in factor IX one-stage assay in samples spiked with nonacog beta pegol among different pairs of reagent\/detection system","volume":"46","author":"Duboscq","year":"2024","journal-title":"Int. J. Lab. Hematol."},{"issue":"6","key":"10.1016\/j.thromres.2026.109655_bb0190","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1111\/j.1538-7836.2012.04705.x","article-title":"Validation of Nijmegen\u2013Bethesda assay modifications to allow inhibitor measurement during replacement therapy and facilitate inhibitor surveillance","volume":"10","author":"Miller","year":"2012","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2026.109655_bb0195","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.omtm.2022.01.005","article-title":"Differential T cell immune responses to deamidated adeno-associated virus vector","volume":"24","author":"Bing","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."},{"issue":"5","key":"10.1016\/j.thromres.2026.109655_bb0200","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1172\/JCI32878","article-title":"Long-term expression of murine activated factor VII is safe, but elevated levels cause premature mortality","volume":"118","author":"Aljamali","year":"2008","journal-title":"J. Clin. Invest."},{"issue":"5","key":"10.1016\/j.thromres.2026.109655_bb0205","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1182\/bloodadvances.2019000405","article-title":"Evolutionary insights into coagulation factor IX Padua and other high-specific-activity variants","volume":"5","author":"Samelson-Jones","year":"2021","journal-title":"Blood Adv."},{"issue":"9","key":"10.1016\/j.thromres.2026.109655_bb0210","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1182\/blood-2017-09-804419","article-title":"Gene therapy with adeno-associated virus vector 5\u2013human factor IX in adults with hemophilia B","volume":"131","author":"Miesbach","year":"2018","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.thromres.2026.109655_bb0215","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1056\/NEJMoa2307159","article-title":"Fidanacogene Elaparvovec for hemophilia B\u2014A multiyear follow-up study","volume":"392","author":"Rasko","year":"2025","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.thromres.2026.109655_bb0220","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1182\/blood.2019004625","article-title":"BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expression","volume":"137","author":"Konkle","year":"2021","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.thromres.2026.109655_bb0225","doi-asserted-by":"crossref","first-page":"e265","DOI":"10.1016\/S2352-3026(24)00006-1","article-title":"Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B): 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trial","volume":"11","author":"Coppens","year":"2024","journal-title":"Lancet Haematol."},{"issue":"1","key":"10.1016\/j.thromres.2026.109655_bb0230","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1182\/blood-2013-01-306647","article-title":"Immune responses to AAV vectors: overcoming barriers to successful gene therapy","volume":"122","author":"Mingozzi","year":"2013","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.thromres.2026.109655_bb0235","doi-asserted-by":"crossref","first-page":"5957","DOI":"10.1182\/bloodadvances.2024014111","article-title":"Adeno-associated virus\u2013based gene therapy for hemophilia a and B: a systematic review and meta-analysis","volume":"8","author":"Deshpande","year":"2024","journal-title":"Blood Adv."},{"issue":"3\u20134","key":"10.1016\/j.thromres.2026.109655_bb0240","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1089\/hum.2023.208","article-title":"Efficacy and safety of adeno-associated virus-based clinical gene therapy for hemophilia: a systematic review and meta-analysis","volume":"35","author":"Han","year":"2024","journal-title":"Hum. Gene Ther."},{"issue":"25","key":"10.1016\/j.thromres.2026.109655_bb0245","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1056\/NEJMoa1108046","article-title":"Adenovirus-associated virus vectormediated gene transfer in hemophilia B","volume":"365","author":"Ac","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2026.109655_bb0250","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1182\/blood-2020-139225","article-title":"AMT-060 gene therapy in adults with severe or moderate-severe hemophilia B confirm stable FIX expression and durable reductions in bleeding and factor IX consumption for up to 5 years","volume":"136","author":"Leebeek","year":"2020","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.thromres.2026.109655_bb0255","doi-asserted-by":"crossref","first-page":"4738","DOI":"10.1021\/acs.molpharmaceut.9b00959","article-title":"Molecular engineering of adeno-associated virus capsid improves its therapeutic gene transfer in murine models of hemophilia and retinal degeneration","volume":"16","author":"Mary","year":"2019","journal-title":"Mol. Pharm."},{"issue":"12","key":"10.1016\/j.thromres.2026.109655_bb0260","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1089\/hum.2019.164","article-title":"Rational engineering and preclinical evaluation of neddylation and SUMOylation site modified adeno-associated virus vectors in murine models of hemophilia B and leber congenital amaurosis","volume":"30","author":"Maurya","year":"2019","journal-title":"Hum. Gene Ther."},{"issue":"22","key":"10.1016\/j.thromres.2026.109655_bb0265","doi-asserted-by":"crossref","first-page":"7827","DOI":"10.1073\/pnas.0802866105","article-title":"Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses","volume":"105","author":"Zhong","year":"2008","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"5","key":"10.1016\/j.thromres.2026.109655_bb0270","doi-asserted-by":"crossref","first-page":"750","DOI":"10.3390\/pharmaceutics13050750","article-title":"Next step in gene delivery: modern approaches and further perspectives of AAV tropism modification","volume":"13","author":"Korneyenkov","year":"2021","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.thromres.2026.109655_bb0275","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41392-024-01800-9","article-title":"Protein neddylation and its role in health and diseases","volume":"9","author":"Zhang","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.thromres.2026.109655_bb0280","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/jimd.12637","article-title":"Liver directed adeno-associated viral vectors to treat metabolic disease","volume":"47","author":"Chuecos","year":"2024","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.thromres.2026.109655_bb0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2023.101147","article-title":"Development of capsid-and genome-modified optimized AAVrh74 vectors for muscle gene therapy","volume":"31","author":"Shoti","year":"2023","journal-title":"Mol. Ther. Methods Clin. Dev."},{"issue":"11","key":"10.1016\/j.thromres.2026.109655_bb0290","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1002\/emmm.201302859","article-title":"Effective gene therapy for haemophilic mice with pathogenic factor IX antibodies","volume":"5","author":"Markusic","year":"2013","journal-title":"EMBO Mol. Med."},{"issue":"1","key":"10.1016\/j.thromres.2026.109655_bb0295","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1038\/s41598-022-04892-x","article-title":"Therapeutic potential of highly functional codon-optimized microutrophin for muscle-specific expression","volume":"12","author":"Starikova","year":"2022","journal-title":"Sci. Rep."},{"issue":"21","key":"10.1016\/j.thromres.2026.109655_bb0300","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1182\/blood.2020006005","article-title":"Gene therapy for hemophilia B using CB 2679d-GT: a novel factor IX variant with higher potency than factor IX Padua","volume":"137","author":"Nair","year":"2021","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.thromres.2026.109655_bb0305","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.ymthe.2019.11.006","article-title":"A molecular revolution in the treatment of hemophilia","volume":"28","author":"Butterfield","year":"2020","journal-title":"Mol. Ther."},{"issue":"23","key":"10.1016\/j.thromres.2026.109655_bb0310","doi-asserted-by":"crossref","first-page":"4517","DOI":"10.1182\/blood-2012-05-432591","article-title":"Hyperfunctional coagulation factor IX improves the efficacy of gene therapy in hemophilic mice","volume":"120","author":"Cantore","year":"2012","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.thromres.2026.109655_bb0315","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1182\/blood-2014-07-588194","article-title":"AAV liver expression of FIX-Padua prevents and eradicates FIX inhibitor without increasing thrombogenicity in hemophilia B dogs and mice","volume":"125","author":"Crudele","year":"2015","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.thromres.2026.109655_bb0320","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.1182\/blood-2013-10-534032","article-title":"Computationally designed liver-specific transcriptional modules and hyperactive factor IX improve hepatic gene therapy (vol 123, pg 3195, 2014)","volume":"123","author":"Nair","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.thromres.2026.109655_bb0325","doi-asserted-by":"crossref","DOI":"10.1172\/JCI143780","article-title":"Overcoming innate immune barriers that impede AAV gene therapy vectors","volume":"131","author":"Muhuri","year":"2021","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.thromres.2026.109655_bb0330","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s12967-017-1200-1","article-title":"Evaluation of engineered AAV capsids for hepatic factor IX gene transfer in murine and canine models","volume":"15","author":"Markusic","year":"2017","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.thromres.2026.109655_bb0335","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.omtm.2019.09.005","article-title":"Enhanced factor IX activity following administration of AAV5-R338L \u201cPadua\u201d factor IX versus AAV5 WT human factor IX in NHPs","volume":"15","author":"Spronck","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"issue":"5","key":"10.1016\/j.thromres.2026.109655_bb0340","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/mus.28228","article-title":"Safety of risdiplam in spinal muscular atrophy patients after short-term treatment with nusinersen","volume":"70","author":"Yan","year":"2024","journal-title":"Muscle Nerve"},{"issue":"6","key":"10.1016\/j.thromres.2026.109655_bb0345","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1089\/hum.2013.238","article-title":"Intracerebral administration of adeno-associated viral vector serotype rh. 10 carrying human SGSH and SUMF1 cDNAs in children with mucopolysaccharidosis type IIIA disease: results of a phase I\/II trial","volume":"25","author":"Tardieu","year":"2014","journal-title":"Hum. Gene Ther."}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384826000745?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384826000745?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T09:21:16Z","timestamp":1778664076000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384826000745"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":69,"alternative-id":["S0049384826000745"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2026.109655","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimized AAVrh10 and Factor 9 vectors demonstrate improved phenotypic rescue in hemophilia B mice","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2026.109655","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109655"}}